Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications

Abstract

Background Androgen deprivation therapy (ADT) in localized prostate cancer improves overall survival and is recommended by National Comprehensive Cancer Network guidelines in certain situations. However, ADT is without benefit in other situations and can actually cause harm. This study examines recent trends in the ADT use and quantifies the cost of guideline-discordant ADT. Patients and methods Patients, aged 66-80 years, in the Surveillance Epidemiology and End Results-Medicare database with non-metastatic prostate cancer diagnosed between 2004 and 2007 were included for analysis. Prostate-specific antigen, Gleason score, and stage were used to define D'Amico risk categories. Logistic regression was used to examine factors associated with guideline-discordant ADT. Annual direct cost was estimated using 2011 Medicare reimbursement for ADT. Results Of 28 654 men included, 12.4% received guideline-discordant ADT. In low-risk patients, 14.9% received discordant ADT, mostly due to simultaneous ADT with radiation. Discordant use was seen in 7.3% of intermediate and 14.9% of high-risk patients, mostly from ADT as primary therapy. The odds of receiving guideline-discordant ADT decreased over time (2007 versus 2004; OR 0.69; 95% CI 0.62-0.76). The estimated annual direct cost from discordant ADT is $42 000 000. Conclusion Approximately one in eight patients received ADT discordant with published guidelines. Elimination of discordant use would result in substantial savings.

Figure 1.

Direct annual costs of discordant ADT use to Medicare assuming the different average durations of therapy. ADT, androgen deprivation therapy. Cost calculated from fourth quarter of 2011 Medicare's most common ADT claim (J9217, $221.07), multiplied by the estimated number of Medicare patients with localized prostate cancer (126 911), the prevalence of guideline discordant therapy (12.4% for all patients, 14.9% low risk), and different potential durations of ADT use (6 months, 1, and 2 years).